The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity
Open accessAbstract
Background T cell tolerance of allergic cutaneous contact sensitivity (CS) induced in mice by high doses of reactive hapten is mediated by suppressor cells that release antigen-specific suppressive nanovesicles. Objective To determine the mechanism(s) of immune suppression mediated by the nanovesicles. Methods T cell tolerance was induced by i.v. injections of hapten conjugated to self antigens of syngeneic erythrocytes and subsequent contact immunization with the same hapten. Lymph node and spleen cells from tolerized or control donors were harvested and cultured to produce a supernatant containing suppressive nanovesicles that were isolated for testing in active and adoptive cell transfer models of CS. Results Tolerance was shown due to exosome-like nanovesicles in the supernatant of CD8+ suppressor T cells that were not Treg. Antigen specificity of the suppressive nanovesicles was conferred by a surface coat of antibody light chains, or possibly whole antibody, allowing targeted delivery of selected inhibitory miRNA-150 to CS effector T cells. Nanovesicles also inhibited CS in actively sensitized mice after systemic injection at the peak of the responses. The role of antibody and miRNA-150 was established by tolerizing either panimmunoglobulin deficient JH-/- or miRNA-150-/- mice that produced non-suppressive nanovesicles. These nanovesicles could be made suppressive by adding antigen-specific antibody light chains or miRNA-150, respectively. Conclusions This is the first example of T cell regulation via systemic transit of exosome-like nanovesicles delivering a chosen inhibitory miRNA to target effector T cells in an antigen-specific manner by a surface coating of antibody light chains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pregnancy-Associated Exosomes and Their Modulation of T Cell Signaling
Taylor, D. D., Akyol, S., & Gercel-Taylor, C. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1534 · Cited by 297
RetractedIsolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766
Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes.
Montecalvo, A., Larregina, A. T., Shufesky, W. J., Beer Stolz, D., Sullivan, M. L. G., Karlsson, J. M., Baty, C. J., Gibson, G. A., Erdos, G., Wang, Z., et al. (2012) · Blood · doi:10.1182/blood-2011-02-338004 · Cited by 1,429
Zhang, L., Hou, D., Chen, X., Li, D., Zhu, L., Zhang, Y., Li, J., Bian, Z., Liang, X., Cai, X., et al. (2012) · Cell Research · doi:10.1038/cr.2011.158 · Cited by 1,216
Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003884 · Cited by 540
Trans-Synaptic Transmission of Vesicular Wnt Signals through Evi/Wntless
Korkut, C., Ataman, B., Ramachandran, P., Ashley, J., Barria, R., Gherbesi, N., & Budnik, V. (2009) · Cell · doi:10.1016/j.cell.2009.07.051 · Cited by 443
Cited by
Advances in therapeutic applications of extracellular vesicles
Wiklander, O. P. B., Brennan, M. Á., Lötvall, J., Breakefield, X. O., & EL Andaloussi, S. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav8521 · Cited by 1,039
Exosomes: Therapy delivery tools and biomarkers of diseases
Barile, L., & Vassalli, G. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.020 · Cited by 1,038
Exosomes: Vehicles of Intercellular Signaling, Biomarkers, and Vectors of Cell Therapy
Kourembanas, S. (2015) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021014-071641 · Cited by 761
Johnsen, K. B., Gudbergsson, J. M., Skov, M. N., Pilgaard, L., Moos, T., & Duroux, M. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.04.005 · Cited by 704
Brites, D., & Fernandes, A. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00476 · Cited by 599
“…are able to knockdown specific proteins in neurons, microglia, and oligodendrocytes in the brain of treated animals, proving the Frontiers in Cellular Neuroscience | www.frontiersin.org 12 December 2015 | Volume 9 | Article 476 therapeutic potential of autologous exosome-based delivery system.”
BackgroundMicroRNA-Containing T-Regulatory-Cell-Derived Exosomes Suppress Pathogenic T Helper 1 Cells
Okoye, I. S., Coomes, S. M., Pelly, V. S., Czieso, S., Papayannopoulos, V., Tolmachova, T., Seabra, M. C., & Wilson, M. S. (2014) · Immunity · doi:10.1016/j.immuni.2014.05.019 · Cited by 605
Mast Cells, Mastocytosis, and Related Disorders
Theoharides, T. C., Valent, P., & Akin, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1409760 · Cited by 518
Therapeutic Applications of Extracellular Vesicles: Clinical Promise and Open Questions
György, B., Hung, M. E., Breakefield, X. O., & Leonard, J. N. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124630 · Cited by 515
Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing
Didiot, M.-C., Hall, L. M., Coles, A. H., Haraszti, R. A., Godinho, B. M., Chase, K., Sapp, E., Ly, S., Alterman, J. F., Hassler, M. R., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.126 · Cited by 483
Exosome engineering: Current progress in cargo loading and targeted delivery
Fu, S., Wang, Y., Xia, X., & Zheng, J. C. (2020) · NanoImpact · doi:10.1016/j.impact.2020.100261 · Cited by 444
Hybrid exosomes, exosome-like nanovesicles and engineered exosomes for therapeutic applications
Mondal, J., Pillarisetti, S., Junnuthula, V., Saha, M., Hwang, S. R., Park, I.-K., & Lee, Y.-K. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.027 · Cited by 416
Exosomes as therapeutics: The implications of molecular composition and exosomal heterogeneity
Ferguson, S. W., & Nguyen, J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.037 · Cited by 416
Gong, C., Tian, J., Wang, Z., Gao, Y., Wu, X., Ding, X., Qiang, L., Li, G., Han, Z., Yuan, Y., et al. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0526-7 · Cited by 339
Non-viral vectors for RNA delivery
Yan, Y., Liu, X.-Y., Lu, A., Wang, X.-Y., Jiang, L.-X., & Wang, J.-C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.008 · Cited by 332
Exosomes as novel bio-carriers for gene and drug delivery
Jiang, X.-C., & Gao, J.-Q. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.02.038 · Cited by 321
Recent advances in exosome-mediated nucleic acid delivery for cancer therapy
Zhang, Y., Liu, Q., Zhang, X., Huang, H., Tang, S., Chai, Y., Xu, Z., Li, M., Chen, X., Liu, J., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01472-z · Cited by 306
The Exosome ‐ A Naturally Secreted Nanoparticle and its Application to Wound Healing
Rani, S., & Ritter, T. (2016) · Advanced Materials · doi:10.1002/adma.201504009 · Cited by 296
Hong, P., Yang, H., Wu, Y., Li, K., & Tang, Z. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1358-y · Cited by 269
Exosome as a Novel Shuttle for Delivery of Therapeutics across Biological Barriers
Das, C. K., Jena, B. C., Banerjee, I., Das, S., Parekh, A., Bhutia, S. K., & Mandal, M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00901 · Cited by 263
Zempleni, J., Aguilar-Lozano, A., Sadri, M., Sukreet, S., Manca, S., Wu, D., Zhou, F., & Mutai, E. (2017) · The Journal of Nutrition · doi:10.3945/jn.116.238949 · Cited by 262
Exosomes as drug carriers for cancer therapy and challenges regarding exosome uptake
Zhao, X., Wu, D., Ma, X., Wang, J., Hou, W., & Zhang, W. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110237 · Cited by 197
Role of Exosomes in the Regulation of T-Cell Mediated Immune Responses and in Autoimmune Disease
(2019) · doi:10.3390/cells8020154 · Cited by 169
Mast cells, brain inflammation and autism
Theoharides, T. C., Stewart, J. M., Panagiotidou, S., & Melamed, I. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.086 · Cited by 138
Harnessing the exosome-induced immune response for cancer immunotherapy
Gehrmann, U., Näslund, T. I., Hiltbrunner, S., Larssen, P., & Gabrielsson, S. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.003 · Cited by 111
Strategies for the use of Extracellular Vesicles for the Delivery of Therapeutics
Sil, S., Dagur, R. S., Liao, K., Peeples, E. S., Hu, G., Periyasamy, P., & Buch, S. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09873-y · Cited by 109
“…type of bioengineered EVs relies on the development of artificial exosomes, exosome-based semisynthetic vesicles, exosomelike nanovesicles, and exosome-mimetic nanovesicles (De La Pena et al. 2009; Bryniarski et al. 2013; Jang et al. 2013; Forterre et al. 2014; Jeong et al. 2014; Yoon et al. 2015).”
Exosomes in neurologic and psychiatric disorders
Tsilioni, I., Panagiotidou, S., & Theoharides, T. C. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.05.005 · Cited by 93
Exosome-like Nanoparticles: A New Type of Nanocarrier
Fernandes, M., Lopes, I., Teixeira, J., Botelho, C., & Gomes, A. C. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867326666190129142604 · Cited by 51
Recent Trends in Nanotechnology Toward CNS Diseases
Cardoso, A. M., Guedes, J. R., Cardoso, A. L., Morais, C., Cunha, P., Viegas, A. T., Costa, R., Jurado, A., & Pedroso de Lima, M. C. (2016) · International Review of Neurobiology · doi:10.1016/bs.irn.2016.05.002 · Cited by 26
Metadata
- Authors
- Bryniarski, K., Ptak, W., Jayakumar, A., Püllmann, K., Caplan, M. J., Chairoungdua, A., Lu, J., Adams, B. D., Sikora, E., Nazimek, K., Marquez, S., Kleinstein, S. H., Sangwung, P., Iwakiri, Y., Delgato, E., Redegeld, F., Blokhuis, B. R., Wojcikowski, J., Daniel, A. W., Groot Kormelink, T., & Askenase, P. W.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2013-07
- Volume
- 132
- Issue
- 1
- Pages
- 170-181.e9
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2033850456
- Cited by
- 215
- References
- 6
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.